Tradename | Company | Number | Date | Products |
---|---|---|---|---|
FARXIGA | AstraZeneca | N-202293 RX | 2014-01-08 | 2 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
QTERN | AstraZeneca | N-209091 RX | 2017-02-27 | 2 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
QTERNMET XR | AstraZeneca | N-210874 DISCN | 2019-05-02 | 4 products, RLD |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
XIGDUO XR | AstraZeneca | N-205649 RX | 2014-10-29 | 5 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
dapagliflozin | NDA authorized generic | 2024-10-24 |
dapagliflozin and metformin hydrochloride | NDA authorized generic | 2024-12-20 |
farxiga | New Drug Application | 2024-10-24 |
qtern | New Drug Application | 2024-11-13 |
xigduo | New Drug Application | 2024-12-20 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
type 2 diabetes mellitus | EFO_0001360 | D003924 | E11 |
Expiration | Code | ||
---|---|---|---|
DAPAGLIFLOZIN, FARXIGA, ASTRAZENECA AB | |||
2024-04-30 | I-857 | ||
2023-05-05 | I-834 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Dapagliflozin, Farxiga, Astrazeneca Ab | |||
10973836 | 2040-03-09 | U-3127 | |
8685934 | 2030-05-26 | U-1522 | |
8721615 | 2030-01-18 | DP | |
7919598 | 2029-12-16 | DP | |
7851502 | 2028-08-19 | DP | |
8221786 | 2028-03-21 | DP | |
8361972 | 2028-03-21 | U-493, U-1976, U-1977, U-2139 | |
8716251 | 2028-03-21 | DP | |
8501698 | 2027-06-20 | DP | U-493, U-1976, U-1977 |
8329648 | 2026-08-18 | U-2139, U-2212, U-2213 | |
8906851 | 2026-08-18 | U-2139 | |
6515117 | 2025-10-04 | DS, DP | U-493, U-2139 |
7456254 | 2025-06-30 | DP | U-2139 |
8431685 | 2025-04-13 | DP | U-2139 |
8461105 | 2025-04-13 | DP | U-2139 |
9238076 | 2024-04-15 | DP | U-2139 |
Dapagliflozin / Metformin Hydrochloride, Xigduo Xr, Astrazeneca Ab | |||
9616028 | 2030-11-12 | DP | |
Dapagliflozin / Metformin Hydrochloride / Saxagliptin Hydrochloride, Qternmet Xr, Astrazeneca Ab | |||
8628799 | 2025-07-13 | DP | |
RE44186 | 2023-07-31 | DS, DP | U-493 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 22 | 9 | 40 | 35 | 20 | 122 |
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 5 | 8 | 35 | 27 | 13 | 85 |
Heart failure | D006333 | EFO_0003144 | I50 | 2 | 2 | 9 | 3 | 8 | 24 |
Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | 9 | 6 | 2 | 5 | 22 |
Chronic renal insufficiency | D051436 | — | N18 | 1 | 9 | 6 | 2 | 4 | 21 |
Hypertension | D006973 | EFO_0000537 | I10 | — | 2 | 6 | 1 | — | 8 |
Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 2 | 1 | 3 | 1 | 1 | 8 |
Albuminuria | D000419 | EFO_0004285 | R80.9 | — | 3 | 1 | 2 | — | 5 |
Obesity | D009765 | EFO_0001073 | E66.9 | — | 2 | 2 | 1 | — | 5 |
Renal insufficiency | D051437 | — | N19 | 1 | 1 | 1 | 2 | — | 5 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Body weight | D001835 | EFO_0004338 | — | — | 3 | 1 | — | — | 4 |
Inferior wall myocardial infarction | D056989 | EFO_1000983 | — | — | — | 1 | — | — | 1 |
Covid-19 | D000086382 | — | U07.1 | — | — | 1 | — | — | 1 |
Respiratory insufficiency | D012131 | — | J96.9 | — | — | 1 | — | — | 1 |
Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | — | 1 | — | — | 1 |
Syndrome | D013577 | — | — | — | — | 1 | — | — | 1 |
Overweight | D050177 | — | E66.3 | — | — | 1 | — | — | 1 |
Death | D003643 | PATO_0001422 | — | — | — | 1 | — | — | 1 |
Left ventricular dysfunction | D018487 | — | — | — | — | 1 | — | — | 1 |
St elevation myocardial infarction | D000072657 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Weight loss | D015431 | — | — | — | 2 | — | — | — | 2 |
Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 2 | — | — | — | 2 |
Diastolic heart failure | D054144 | EFO_1000899 | I50.30 | — | 1 | — | — | — | 1 |
Asymptomatic diseases | D058070 | — | — | — | 1 | — | — | — | 1 |
Hyperuricemia | D033461 | — | — | — | 1 | — | — | — | 1 |
Exercise | D015444 | EFO_0000483 | — | — | 1 | — | — | — | 1 |
Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 10 | — | — | — | — | 10 |
Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | — | — | 1 | 1 |
Diabetic cardiomyopathies | D058065 | EFO_1001458 | — | — | — | — | — | 1 | 1 |
Infections | D007239 | EFO_0000544 | — | — | — | — | — | 1 | 1 |
Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | — | — | — | 1 | 1 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 1 | 1 |
Urinary bladder neoplasms | D001749 | — | C67 | — | — | — | — | 1 | 1 |
Wounds and injuries | D014947 | — | T14.8 | — | — | — | — | 1 | 1 |
Chemical and drug induced liver injury | D056486 | EFO_0004228 | — | — | — | — | — | 1 | 1 |
Acute kidney injury | D058186 | — | N17 | — | — | — | — | 1 | 1 |
Systolic heart failure | D054143 | EFO_1001207 | I50.20 | — | — | — | — | 1 | 1 |
Drug common name | Dapagliflozin |
INN | dapagliflozin |
Description | Dapagliflozin is a C-glycosyl comprising beta-D-glucose in which the anomeric hydroxy group is replaced by a 4-chloro-3-(4-ethoxybenzyl)phenyl group. Used (in the formo f its propanediol monohydrate) to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes. It has a role as a hypoglycemic agent and a sodium-glucose transport protein subtype 2 inhibitor. It is a C-glycosyl compound, an organochlorine compound and an aromatic ether. |
Classification | Small molecule |
Drug class | phlorozin derivatives, phenolic glycosides |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1 |
PDB | — |
CAS-ID | 461432-26-8 |
RxCUI | — |
ChEMBL ID | CHEMBL429910 |
ChEBI ID | 85078 |
PubChem CID | 9887712 |
DrugBank | DB06292 |
UNII ID | 1ULL0QJ8UC (ChemIDplus, GSRS) |